Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Reps Tussle over Product Coverage Threshold for Off-Year Price Revision
November 17, 2022
- Evrenzo to Add Hypothyroidism Risk in Label Revision
November 17, 2022
- MHLW Unveils Overview of Genome Analysis Project Organ for FY2025 Launch
November 17, 2022
- MHLW to Run Health Survey for COVID-19 Vaccination in Children
November 16, 2022
- LDP Legislators Push for “No Off-Year Price Revision”: Health Committee
November 16, 2022
- LDP Lawmakers Throw Support Behind Pharma on Off-Year Plan
November 15, 2022
- Japan’s 4th Avastin Biosimilar, Kit Products Get Listing; No Follow-On for New API in FY2022
November 15, 2022
- LEO Pharma’s Atopic Dermatitis Med Tralokinumab Up for MHLW Panel Review on November 28
November 15, 2022
- Shionogi’s COVID Pill Up for 3rd Round of Discussion for Emergency Approval on Nov. 22
November 15, 2022
- Teikoku’s Donepezil Tape, AbbVie’s Parkinson’s Med Up for PAFSC Review on Nov. 25
November 14, 2022
- 2 Women Die after BA.5 COVID Booster Shots: MHLW
November 14, 2022
- Kokando Told to Suspend Business for Up to 36 Days over Decades-Long Violations
November 14, 2022
- Online Submissions for Generic Approval to Start from January
November 14, 2022
- Pro-Industry Lawmakers, Govt Remain Widely Divided over Off-Year Plan
November 11, 2022
- MHLW Reserves Extra Budget to Build Gene Therapy Support Consortium
November 11, 2022
- Drug Price Negotiations by Consultants Might Violate Distribution Guidelines: Official
November 11, 2022
- Zero Coefficient Rule Hits All 10 Premium-Granted Drugs Priced by Cost Formula in FY2022
November 11, 2022
- Japan to Roll Out Moderna’s BA.4/5 Booster from Nov. 28
November 11, 2022
- Expert Panel Discussion Summary Reported to Chuikyo; Payer Rep Sees No Need for Inflation Response in Off Year
November 10, 2022
- Polivy Likely to Escape CEA-Based Price Tweaks
November 10, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…